Assessment of Naive Indolent Lymphoma Using Whole-body Diffusion-weighted Imaging and T2-weighted MRI: Results of a Prospective Study in 30 Patients

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2021 Jan 8

PMID 33413685

Citations 2

Authors

Gil-Sun Hong

Eun Jin Chae

Jin-Sook Ryu

Sun Young Chae

Hyo Sang Lee

Dok Hyun Yoon

Cheolwon Suh

Affiliations

Soon will be listed here.

Abstract

Background: We prospectively evaluated the diagnostic utility of whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery MRI (WB-DWIBS/STIR) for the pretherapeutic staging of indolent lymphoma in 30 patients.

Methods: This prospective study included 30 treatment-naive patients with indolent lymphomas who underwent WB-DWIBS/STIR and conventional imaging workup plus biopsy. The pretherapeutic staging agreement, sensitivity, and specificity of WB-DWIBS/STIR were investigated with reference to the multimodality and multidisciplinary consensus review for nodal and extranodal lesions excluding bone marrow.

Results: In the pretherapeutic staging, WB-DWIBS/STIR showed very good agreement (κ = 0.96; confidence interval [CI], 0.88-1.00), high sensitivity (93.4-95.1%), and high specificity (99.0-99.4%) for the whole-body regions. These results were similar to those of F-FDG-PET/CT, except for the sensitivity for extranodal lesions. For extranodal lesions, WB-DWIBS/STIR showed higher sensitivity compared to F-FDG-PET/CT for the whole-body regions (94.9-96.8% vs. 79.6-86.3%, P = 0.058).

Conclusion: WB-DWIBS/STIR is an effective modality for the pretherapeutic staging of indolent lymphoma, and it has benefits when evaluating extranodal lesions, compared with F-FDG-PET/CT.

Citing Articles

Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients.

Lambert L, Wagnerova M, Vodicka P, Benesova K, Zogala D, Trneny M World J Radiol. 2025; 17(1):99207.

PMID: 39876887 PMC: 11755907. DOI: 10.4329/wjr.v17.i1.99207.

Unraveling the complexity of follicular lymphoma: insights and innovations.

Li X, Li N, Liu Y, An L Am J Cancer Res. 2025; 14(12):5573-5597.

PMID: 39803651 PMC: 11711519. DOI: 10.62347/MFUG2190.

Melanoma in pregnancy.

Czeyda-Pommersheim F, Kluger H, Langdon J, Menias C, VanBuren W, Leventhal J Abdom Radiol (NY). 2023; 48(5):1740-1751.

PMID: 36719425 DOI: 10.1007/s00261-022-03796-8.

The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis.

Lambert L, Burgetova A, Trneny M, Bircakova B, Molinsky J, Benesova K Quant Imaging Med Surg. 2022; 12(2):1558-1570.

PMID: 35111648 PMC: 8739096. DOI: 10.21037/qims-21-649.

References

Albano D, Patti C, La Grutta L, Agnello F, Grassedonio E, Mule A . Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol. 2016; 85(2):313-8. DOI: 10.1016/j.ejrad.2015.12.006. View

Galia M, Albano D, Tarella C, Patti C, Sconfienza L, Mule A . Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now. Eur Radiol. 2017; 28(3):1187-1193. DOI: 10.1007/s00330-017-5071-x. View

Ferrari C, Minoia C, Niccoli Asabella A, Nicoletti A, Altini C, Antonica F . Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma. Hell J Nucl Med. 2014; 17 Suppl 1:40-9. View

Radan L, Fischer D, Bar-Shalom R, Dann E, Epelbaum R, Haim N . FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008; 35(8):1424-30. DOI: 10.1007/s00259-008-0771-8. View

Wang D, Huo Y, Chen S, Wang H, Ding Y, Zhu X . Whole-body MRI versus F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis. Onco Targets Ther. 2018; 11:3597-3608. PMC: 6016278. DOI: 10.2147/OTT.S148189. View

Armitage J . Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005; 55(6):368-76. DOI: 10.3322/canjclin.55.6.368. View

Taylor S, Mallett S, Ball S, Beare S, Bhatnagar G, Bhowmik A . Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respir Med. 2019; 7(6):523-532. PMC: 6529610. DOI: 10.1016/S2213-2600(19)30090-6. View

Pawlyn C, Fowkes L, Otero S, Jones J, Boyd K, Davies F . Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?. Leukemia. 2015; 30(6):1446-8. PMC: 4895156. DOI: 10.1038/leu.2015.338. View

Mayerhoefer M, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C . Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res. 2014; 20(11):2984-93. DOI: 10.1158/1078-0432.CCR-13-3355. View

10.

Kwee T, Takahara T, Ochiai R, Nievelstein R, Luijten P . Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008; 18(9):1937-52. PMC: 2516183. DOI: 10.1007/s00330-008-0968-z. View

11.

Albano D, La Grutta L, Grassedonio E, Patti C, Lagalla R, Midiri M . Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: What radiologists should know. Magn Reson Imaging. 2016; 34(7):922-31. DOI: 10.1016/j.mri.2016.04.023. View

12.

Gu J, Chan T, Zhang J, Leung A, Kwong Y, Khong P . Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol. 2011; 197(3):W384-91. DOI: 10.2214/AJR.10.5692. View

13.

Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi Y . Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23(21):4643-51. DOI: 10.1200/JCO.2005.12.072. View

14.

de Jong P, van Ufford H, Baarslag H, de Haas M, Wittebol S, Quekel L . CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol. 2009; 192(3):745-53. DOI: 10.2214/AJR.08.1160. View

15.

Kwee T, Vermoolen M, Akkerman E, Kersten M, Fijnheer R, Ludwig I . Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J Magn Reson Imaging. 2013; 40(1):26-36. DOI: 10.1002/jmri.24356. View

16.

Cronin C, Swords R, Truong M, Viswanathan C, Rohren E, Giles F . Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2009; 194(1):W91-W103. DOI: 10.2214/AJR.09.2637. View

17.

Taylor S, Mallett S, Miles A, Beare S, Bhatnagar G, Bridgewater J . Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L). BMC Cancer. 2017; 17(1):299. PMC: 5412056. DOI: 10.1186/s12885-017-3281-x. View

18.

Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A . The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health.... Cancer. 2007; 110(3):652-9. DOI: 10.1002/cncr.22807. View

19.

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

20.

Brenner D, Hall E . Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007; 357(22):2277-84. DOI: 10.1056/NEJMra072149. View